Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke

Charité University Medicine Berlin

Status: Unknown

Conditions: First Ischemic Stroke

Treatments: Other: oral triglyceride tolerance test (not a therapeutic "intervention" as such but a new diagnostic test)

Study type: Observational

Funder types: Other

Identifiers

NCT01378468

The Berlin 'Cream&Sugar' Study

2009-010356-97 (EudraCT Number)

Details and patient eligibility

About

Non-fasting triglyceride levels are thought to play a role in stroke. The investigators hypothesise that the results of a standardised oral triglyceride tolerance test in the subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of recurrent stroke within 12 months after the index event.

Full description

Since high postprandial triglycerides levels may be a risk factor for stroke, we use a combined oral triglyceride and glucose tolerance test in patients who had a first ischemic stroke. Follow-up after one year primarily assesses wether or not a recurrent stroke has occured. The glucose tolerance test is meant to identify patients with metabolic syndrome (and diabetes), since this condition is per se associated with increased levels of triglycerides. Potentially, the post-challenge triglyceride levels only play a role in patients without diabetes or metabolic syndrome. For further details see Ebinger et al. 'The Berlin 'Cream&Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in patients after acute ischaemic stroke', IJS; 2010,5, 47-51.

Enrollment: 573 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age over 18 years
• First ischemic stroke
• Incidence within less than 7 days
• Informed consent obtained

Exclusion criteria

• Aphasia (if hampering informed consent)
• Swallowing disorder
• Pregnancy
• Renal or hepatic failure
• Pancreatitis
• Cholecystolithiasis
• Malabsorption
• Lactose intolerance
• Psychosis
• Drug and/or alcohol addiction
• Expected life expectancyr12 months
• Inability to sign informed consent
• Acute coronary syndrome
• Severe heart valve disorder
• Heart failure (NYHA III-IV)
• Severe infectious/rheumatic disease
• Sever metabolic disease
• No oral glucose tolerance test in case of known diabetes

Trial design

573 participants in 1 patient group

Patients with first ischemic stroke

Treatment:

Other: oral triglyceride tolerance test (not a therapeutic "intervention" as such but a new diagnostic test)